STK11 and cancer: Deletion, mutation, or a reduced expression of LKB1 has been demonstrated to increase the risk of malignant tumors in lungs, colon, breast, cervical, gastrointestinal, and pancreatic tissues through AMP-activated protein kinase (AMPK)-mediated metabolic reprogramming [43].